BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

794 related articles for article (PubMed ID: 26940766)

  • 41. Initial Experience with the Radiotracer 18F-Fluciclovine PET/CT in Ovarian Cancer.
    Buehner TM; Liotta M; Potkul RK; Wagner RH; Savir-Baruch B
    Mol Imaging Biol; 2024 Feb; 26(1):45-52. PubMed ID: 36754935
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The role of (18)F-FDG PET/CT in the diagnosis of breast cancer and lymph nodes metastases and micrometastases may be limited.
    Zhang X; Wu F; Han P
    Hell J Nucl Med; 2014; 17(3):177-83. PubMed ID: 25526754
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Diagnostic and prognostic value of (18)F-FDG PET/CT for axillary lymph node staging in patients with breast cancer.
    Kitajima K; Fukushima K; Miyoshi Y; Katsuura T; Igarashi Y; Kawanaka Y; Mouri M; Maruyama K; Yamano T; Doi H; Yamakado K; Hirota S; Hirota S
    Jpn J Radiol; 2016 Mar; 34(3):220-8. PubMed ID: 26715510
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Appearance of untreated bone metastases from breast cancer on FDG PET/CT: importance of histologic subtype.
    Dashevsky BZ; Goldman DA; Parsons M; Gönen M; Corben AD; Jochelson MS; Hudis CA; Morrow M; Ulaner GA
    Eur J Nucl Med Mol Imaging; 2015 Oct; 42(11):1666-1673. PubMed ID: 25971426
    [TBL] [Abstract][Full Text] [Related]  

  • 45. 18F-FDG semi-quantitative parameters and biological prognostic factors in locally advanced breast cancer.
    García Vicente AM; Soriano Castrejón A; Relea Calatayud F; Muñoz Madero V; Molina Garrido MJ; León Martín AA; Cordero García JM; Pilkington Woll JP; Chacón López-Muñiz I; Palomar Muñoz A
    Rev Esp Med Nucl Imagen Mol; 2012; 31(6):308-14. PubMed ID: 23084013
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The sensitivity of pre-operative axillary staging in breast cancer: comparison of invasive lobular and ductal carcinoma.
    Topps A; Clay V; Absar M; Howe M; Lim Y; Johnson R; Bundred N
    Eur J Surg Oncol; 2014 Jul; 40(7):813-7. PubMed ID: 24797703
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prognostic value of primary tumor SUV
    Yoo J; Yoon HJ; Kim BS
    Ann Nucl Med; 2017 Jan; 31(1):19-28. PubMed ID: 27645144
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma.
    Schuster DM; Votaw JR; Nieh PT; Yu W; Nye JA; Master V; Bowman FD; Issa MM; Goodman MM
    J Nucl Med; 2007 Jan; 48(1):56-63. PubMed ID: 17204699
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prospective evaluation of
    Jambor I; Kuisma A; Kähkönen E; Kemppainen J; Merisaari H; Eskola O; Teuho J; Perez IM; Pesola M; Aronen HJ; Boström PJ; Taimen P; Minn H
    Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):355-364. PubMed ID: 29147764
    [TBL] [Abstract][Full Text] [Related]  

  • 50. (18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) versus (11)C-choline PET/CT in prostate cancer relapse: results of a prospective trial.
    Nanni C; Zanoni L; Pultrone C; Schiavina R; Brunocilla E; Lodi F; Malizia C; Ferrari M; Rigatti P; Fonti C; Martorana G; Fanti S
    Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1601-10. PubMed ID: 26960562
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Whole-Body Metabolic Tumor Volume, as Determined by (18)F-FDG PET/CT, as a Prognostic Factor of Outcome for Patients With Breast Cancer Who Have Distant Metastasis.
    Son SH; Lee SW; Jeong SY; Song BI; Chae YS; Ahn BC; Lee J
    AJR Am J Roentgenol; 2015 Oct; 205(4):878-85. PubMed ID: 26204115
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Role of 18F-FDG PET/CT in evaluating molecular subtypes and clinicopathological features of primary breast cancer.
    Arslan E; Çermik TF; Trabulus FDC; Talu ECK; Başaran Ş
    Nucl Med Commun; 2018 Jul; 39(7):680-690. PubMed ID: 29893750
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [
    Zanoni L; Bianchi L; Nanni C; Pultrone C; Giunchi F; Bossert I; Matti A; Schiavina R; Fiorentino M; Romagnoli D; Fonti C; Lodi F; D'Errico A; Brunocilla E; Porreca A; Fanti S
    Eur J Nucl Med Mol Imaging; 2021 Dec; 49(1):390-409. PubMed ID: 34213609
    [TBL] [Abstract][Full Text] [Related]  

  • 54. (18)F-FDG-PET/CT for systemic staging of newly diagnosed triple-negative breast cancer.
    Ulaner GA; Castillo R; Goldman DA; Wills J; Riedl CC; Pinker-Domenig K; Jochelson MS; Gönen M
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1937-44. PubMed ID: 27129866
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prospective evaluation of fluciclovine (
    Akin-Akintayo O; Tade F; Mittal P; Moreno C; Nieh PT; Rossi P; Patil D; Halkar R; Fei B; Master V; Jani AB; Kitajima H; Osunkoya AO; Ormenisan-Gherasim C; Goodman MM; Schuster DM
    Eur J Radiol; 2018 May; 102():1-8. PubMed ID: 29685521
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Impact of
    Jani AB; Schreibmann E; Rossi PJ; Shelton J; Godette K; Nieh P; Master VA; Kucuk O; Goodman M; Halkar R; Cooper S; Chen Z; Schuster DM
    J Nucl Med; 2017 Mar; 58(3):412-418. PubMed ID: 27609792
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Do 18F-FDG PET/CT findings have a relationship with histopathological and immunohistochemical factors of breast cancer in men?
    Vatankulu B; Işik G; Kocael P; Kuyumcu S; Ilvan Ş; Sağer S; Halaç M; Türkmen C; Sönmezoğlu K
    Nucl Med Commun; 2016 Dec; 37(12):1273-1281. PubMed ID: 27472037
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Simultaneous whole-body ¹⁸F-FDG PET-MRI in primary staging of breast cancer: a pilot study.
    Taneja S; Jena A; Goel R; Sarin R; Kaul S
    Eur J Radiol; 2014 Dec; 83(12):2231-2239. PubMed ID: 25282709
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Detection of internal mammary lymph node metastasis with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with stage III breast cancer.
    Seo MJ; Lee JJ; Kim HO; Chae SY; Park SH; Ryu JS; Ahn SH; Lee JW; Son BH; Gong GY; Moon DH
    Eur J Nucl Med Mol Imaging; 2014 Mar; 41(3):438-45. PubMed ID: 24196918
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Metabolic and volume-based parameters of (18F)FDG PET/CT for primary mass and axillary lymph node metastasis in patients with invasive ductal carcinoma: a retrospective analysis in relation to molecular subtype, axillary lymph node metastasis and immunohistochemistry and inflammatory markers.
    Can C; Komek H
    Nucl Med Commun; 2019 Oct; 40(10):1051-1059. PubMed ID: 31365497
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.